Versanis Bios Announces Acquisition by Eli Lilly
Cooley advised Versanis Bio, a clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases, on patent matters relating to its acquisition by Eli Lilly. Versanis Bios Announces Acquisition by Eli Lilly
Travere Sells Bile Acid Product Portfolio to Mirum
Cooley advised Travere Therapeutics, a biopharmaceutical company, on its definitive agreement to sell its bile acid product portfolio to Mirum Pharmaceuticals for up to $445 million. Travere Sells Bile Acid Product Portfolio to Mirum
CyberGRX Combines With ProcessUnity
Cooley advised CyberGRX, a third-party risk management company, on its definitive merger agreement with ProcessUnity. CyberGRX Combines With ProcessUnity
Liminal BioSciences to Be Acquired by Structured Alpha
Cooley advised Liminal BioSciences, a Canada-based development-stage biopharmaceutical company listed on Nasdaq, on its all-cash cross-border sale to Structured Alpha, a fund managed by Thomvest Asset Management. Liminal BioSciences to Be Acquired by Structured Alpha
DigitalOcean Acquires Paperspace for $111 Million
Cooley advised DigitalOcean, a cloud computing solution for small and medium-sized businesses and startups, on its acquisition of Paperspace for $111 million. DigitalOcean Acquires Paperspace for $111 Million
Morphimmune Announces Merger With Immunome and $125 Million Private Investment
Cooley advised Morphimmune, a private biotechnology company, on its definitive merger agreement with Immunome. Morphimmune Announces Merger With Immunome and $125 Million Private Investment
ThoughtSpot Acquires Mode Analytics
Cooley advised ThoughtSpot, an artificial intelligence-powered analytics company, on its definitive agreement to acquire Mode Analytics, a business intelligence platform, for $200 million. ThoughtSpot Acquires Mode Analytics
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics and Concurrent PIPE Investment
Cooley advised Aeglea BioTherapeutics, a clinical-stage biotechnology company, on its acquisition of Spyre Therapeutics and concurrent private investment. Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics and Concurrent PIPE Investment
Tourmaline Bio Agrees to Merge With Talaris Therapeutics
Cooley advised Tourmaline Bio, a late-stage clinical biotechnology company, on its merger agreement with Talaris Therapeutics, including a concurrent private placement. Tourmaline Bio Agrees to Merge With Talaris Therapeutics
Thirty Madison Acquires Assets From The Pill Club in Section 363 Sale
Cooley advised Thirty Madison, a family of specialized healthcare brands, in its acquisition of certain assets from The Pill Club, following a sale process conducted by The Pill Club under Section 363 of the US Bankruptcy Code. Thirty Madison Acquires Assets From The Pill Club in Section 363 Sale